Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
An accomplished R&D leader and champion of the application of AI to drug discovery
This product has sales of about US$ 20 million in Europe
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Receives registration of Valganciclovir powder for oral solution in Germany
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Subscribe To Our Newsletter & Stay Updated
